POISE
2008
PeriOperative ISchemic Evaluation trial
In 8,351 patients with or at risk of atherosclerotic disease undergoing non-cardiac surgery, extended-release metoprolol started hours before surgery reduced cardiovascular death, non-fatal myocardial infarction or non-fatal cardiac arrest at 30 days but increased death and stroke compared with placebo.
Result
Efficacy: Composite of cardiovascular death, non-fatal MI or non-fatal cardiac arrest at 30 daysHR 0.84 (95% CI 0.70-0.99) · P = 0.04
Safety: StrokeHR 2.17 · P = 0.005
Below 1 favours extended-release metoprolol started hours before surgery, above 1 favours placebo.
Event rates Extended-release metoprolol started hours before surgery 5.8% vs placebo 6.9% (composite of cardiovascular death, non-fatal MI or non-fatal cardiac arrest at 30 days)
Also reported: But all-cause death 3.1 % vs 2.3 % (HR 1.33; p=0.03) and .
- Subtopic
- Beta-blockade
- Design
- Double-blind, placebo-controlled RCT
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- POISE Study Group; Devereaux PJ, Yang H, et al. Lancet. 2008;371(9627):1839-1847.doi 10.1016/S0140-6736(08)60601-7
Discussion & critique
A fixed high dose given without titration hours before surgery, so the excess hypotension, stroke and death may reflect the dosing strategy rather than beta-blockade itself. It is the largest perioperative beta-blocker trial and directly drives the recommendation against starting high-dose beta-blockers immediately before surgery.